[go: up one dir, main page]

DE60040383D1 - Gentherapie für diabetische ischämie - Google Patents

Gentherapie für diabetische ischämie

Info

Publication number
DE60040383D1
DE60040383D1 DE60040383T DE60040383T DE60040383D1 DE 60040383 D1 DE60040383 D1 DE 60040383D1 DE 60040383 T DE60040383 T DE 60040383T DE 60040383 T DE60040383 T DE 60040383T DE 60040383 D1 DE60040383 D1 DE 60040383D1
Authority
DE
Germany
Prior art keywords
gene therapy
diabetic
diabetic ischemia
ischemia
ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60040383T
Other languages
English (en)
Inventor
Ryuichi Morishita
Toshio Ogihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Application granted granted Critical
Publication of DE60040383D1 publication Critical patent/DE60040383D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
DE60040383T 1999-10-29 2000-10-26 Gentherapie für diabetische ischämie Expired - Lifetime DE60040383D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30998499 1999-10-29
PCT/JP2000/007502 WO2001032220A1 (fr) 1999-10-29 2000-10-26 Therapie genique pour traiter les maladies ischemiques diabetiques

Publications (1)

Publication Number Publication Date
DE60040383D1 true DE60040383D1 (de) 2008-11-13

Family

ID=17999746

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040383T Expired - Lifetime DE60040383D1 (de) 1999-10-29 2000-10-26 Gentherapie für diabetische ischämie

Country Status (15)

Country Link
US (3) US20080268030A1 (de)
EP (1) EP1142590B8 (de)
JP (1) JP3877148B2 (de)
KR (1) KR20010108053A (de)
CN (1) CN1182874C (de)
AT (1) ATE409494T1 (de)
AU (1) AU778826B2 (de)
CA (1) CA2356701C (de)
CY (1) CY1110445T1 (de)
DE (1) DE60040383D1 (de)
DK (1) DK1142590T3 (de)
ES (1) ES2313907T3 (de)
HK (1) HK1041211A1 (de)
PT (1) PT1142590E (de)
WO (1) WO2001032220A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038869D1 (de) 1999-10-08 2008-06-26 Anges Mg Inc Hgf zur gentherapie der karidomyopathie
US7247620B2 (en) 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
WO2003045439A1 (fr) 2001-11-28 2003-06-05 Anges Mg, Inc. Preparations medicinales contenant du materiel genetique destinees au traitement de maladies neurodegeneratives
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
CA2500278A1 (en) * 2002-10-02 2004-04-15 Anges Mg, Inc. Pharmaceutical preparation for hearing impairment
JP4775940B2 (ja) * 2004-06-29 2011-09-21 アンジェスＭｇ株式会社 アロディニアの治療、改善、予防剤
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CN102046792B (zh) * 2008-04-09 2014-12-10 百疗医株式会社 用于提高质粒dna表达的冻干dna制剂
JP5977440B2 (ja) * 2012-04-27 2016-08-24 アイマゴ ソシエテ アノニムＡｉｍａｇｏ Ｓ．Ａ． 光コヒーレントイメージング医療デバイス
KR101779775B1 (ko) 2013-10-22 2017-09-21 주식회사 바이로메드 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물
RU2691654C1 (ru) * 2018-06-05 2019-06-17 Юрий Валентинович Червяков Способ лечения хронической ишемии нижних конечностей атеросклеротического генеза при окклюзии бедренной и подколенной артерий
BR112021000722A2 (pt) 2018-07-19 2021-05-04 Helixmith Co., Ltd. composições farmacêuticas liofilizadas para terapia gênica de dna nu
WO2024186828A1 (en) 2023-03-06 2024-09-12 Wisconsin Alumni Research Foundation Methods of inducing cardiac cell proliferation and inducing heart regeneration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576177A (en) * 1983-02-18 1986-03-18 Webster Wilton W Jr Catheter for removing arteriosclerotic plaque
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5817022A (en) * 1995-03-28 1998-10-06 Sonometrics Corporation System for displaying a 2-D ultrasound image within a 3-D viewing environment
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
ES2240999T3 (es) * 1995-08-29 2005-10-16 Anges Mg, Inc. Medicamento que contiene un gen del hgf.
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5922685A (en) * 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
US6893664B1 (en) * 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
ATE465257T1 (de) * 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6024703A (en) * 1997-05-07 2000-02-15 Eclipse Surgical Technologies, Inc. Ultrasound device for axial ranging
GB9709453D0 (en) * 1997-05-10 1997-07-02 Imp Cancer Res Tech Polypedtides and their use in therapy
WO1999036103A1 (en) * 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
CA2261255A1 (en) * 1998-02-13 1999-08-13 Ethicon, Inc. Assessment of ischemic wound healing therapeutics
US6066123A (en) * 1998-04-09 2000-05-23 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of bioavailability by use of focused energy delivery to a target tissue
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
CA2365434A1 (en) * 1999-04-15 2000-10-26 St. Elizabeth's Medical Center Of Boston Angiogenic growth factors for treatment of peripheral neuropathy
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
DE60038869D1 (de) * 1999-10-08 2008-06-26 Anges Mg Inc Hgf zur gentherapie der karidomyopathie
CA2413768A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Pharmaceutical compositions for angiogenic therapy
US7247620B2 (en) * 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
WO2003103721A1 (ja) * 2002-06-06 2003-12-18 アンジェス エムジー株式会社 脳血管障害遺伝子治療剤
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
EP1567197B1 (de) * 2002-12-02 2010-07-21 AnGes MG, Inc. Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen

Also Published As

Publication number Publication date
PT1142590E (pt) 2008-10-27
US20080268030A1 (en) 2008-10-30
DK1142590T3 (da) 2009-01-26
CN1339973A (zh) 2002-03-13
EP1142590A1 (de) 2001-10-10
AU778826B2 (en) 2004-12-23
CN1182874C (zh) 2005-01-05
HK1041211A1 (zh) 2002-07-05
ES2313907T3 (es) 2009-03-16
JP3877148B2 (ja) 2007-02-07
US20110045061A1 (en) 2011-02-24
CA2356701C (en) 2011-02-15
EP1142590B8 (de) 2008-11-26
KR20010108053A (ko) 2001-12-07
EP1142590B1 (de) 2008-10-01
AU1052301A (en) 2001-05-14
WO2001032220A1 (fr) 2001-05-10
EP1142590A4 (de) 2005-01-26
US20160250290A1 (en) 2016-09-01
ATE409494T1 (de) 2008-10-15
CY1110445T1 (el) 2015-04-29
CA2356701A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
CY1110445T1 (el) Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια
DE60138709D1 (de) Analoge der barbitursäure als therapeutische wirkstoffe
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
DE60016393D1 (de) Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
BR0012450A (pt) Benzimidazóis substituìdos
ES2168359T3 (es) Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora.
DK92688A (da) Polypeptid, dna og anvendelse deraf
ATE242267T1 (de) Extendin-4 konjugate und ihre medizinische verwendung
EP1202736A4 (de) Verwendung von nikotin in der angiogenese und der vaskulogenese
DK1401853T3 (da) Modulatorer af farmakologiske midler
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EE05302B1 (et) 4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks
PE20020746A1 (es) Moduladores de receptores cannabinoides, sus procesos de preparacion y uso de los moduladores de receptores cannabinoides para el tratamiento de enfermedades respiratorias y no respiratorias
DE69832702D1 (de) Menschliche chinon reduktase konjugate für adept und gdept
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
ATE408402T1 (de) Stickstoffmonoxid-donoren zum induzieren von neurogenese
ATE516366T1 (de) Regulierte aptamer-therapeutika
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
IT1317930B1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
ES2169124T3 (es) Acido 4-aminomicofenolico 6-sustituido y derivados con actividad inmunosupresora.
HUP0103557A2 (hu) Antraciklinszármazék alkalmazása májtumor kezelésére
HUP9800247A2 (hu) Humán endoglin gén promóter és annak alkalmazása

Legal Events

Date Code Title Description
8364 No opposition during term of opposition